Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 123, Issue 1, Pages 11-18Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI62876
Keywords
-
Categories
Funding
- NIH
- Leducq Foundation
- Robert A. Welch Foundation
- American Heart Association: Jon Holden DeHaan Foundation
- National Heart, Lung, and Blood Institute [1F30HL103013]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL103013, R01HL093039, R01HL077439, R01HL111665] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK099653] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The management of cardiovascular risk through lifestyle modification and pharmacotherapy is paramount to the prevention of cardiovascular disease. Epidemiological studies have identified obesity, dyslipidemia, diabetes, and hypertension as interrelated factors that negatively affect cardiovascular health. Recently, genetic and pharmacological evidence in model systems has implicated microRNAs as dynamic modifiers of disease pathogenesis. An expanded understanding of the function of microRNAs in gene regulatory networks associated with cardiovascular risk will enable identification of novel genetic mechanisms of disease and inform the development of innovative therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available